© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Daniel Pollyea, MD, MS, discusses the current treatment options for acute myeloid leukemia.
September 24th 2021
Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.
A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.
Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.
An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.
Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.